Printer Friendly

MILES' MYCELEX TROCHE GIVEN NEW PROPHYLAXIS INDICATION FOR ORAL THRUSH IN IMMUNOCOMPROMISED PATIENTS

 MILES' MYCELEX TROCHE GIVEN NEW PROPHYLAXIS INDICATION
 FOR ORAL THRUSH IN IMMUNOCOMPROMISED PATIENTS
 WEST HAVEN, Conn., Oct. 30 /PRNewswire/ -- The Pharmaceutical Division of Miles Inc. announced today it received regulatory approval to market its Mycelex (clotrimazole) Troche medication for the prophylactic treatment of oral fungal infections in immunocompromised patients.
 Mycelex (clotrimazole) Troche is the first oral anti-fungal medication to be indicated for both treatment and prevention of oropharyngeal candidiasis, commonly known as "oral thrush." Oral thrush is a painful irritation and ulceration in the mouth frequently experienced by immunocompromised patients including certain cancer patients or renal transplant patients.
 Studies show that Mycelex (clotrimazole) Troche has rates of prevention ranging from 86 to 100 percent when used at its recommended three times daily dosage for prophylaxis.
 The Mycelex (clotrimazole) Troche is a nearly tasteless lozenge which slowly dissolves in the mouth releasing the active drug. Its slow release creates a drug level in saliva which inhibits the fungal growth for up to three hours. Patients have found the Mycelex (clotrimazole) Troche to be highly palatable and convenient to use. Nausea and vomiting have been associated with the drug in about 5 percent of patients. Abnormal liver function tests have been reported in a small number of patients in clinical trials.
 In 1983, Mycelex (clotrimazole) Troche joined the Mycelex prescription product line alongside other dosage forms including Mycelex-G 1 percent Topical Cream and Solution, Mycelex 1 percent Vaginal Cream and 100 and 500 mg Vaginal Tablets. Miles also markets clotrimazole in some non-prescription formulations.
 Miles Inc. is a Fortune 100, research-based company with major businesses in chemicals, health care and imaging technologies. Headquartered in Pittsburgh, Miles employs some 26,000 people at its operations throughout North America. In 1991, the company's sales were $6.2 billion.
 -0- 10/30/92
 /CONTACT: Donald Hyman of Miles, 203-498-6545/ CO: Miles Inc. ST: Pennsylvania IN: MTC SU: PDT


AH -- NY056 -- 7178 10/30/92 14:09 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 30, 1992
Words:322
Previous Article:GRANITE BROADCASTING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE NINE MONTHS AND THIRD QUARTER ENDED SEPTEMBER 30, 1992
Next Article:AWT SUBSIDIARY TO PROVIDE UP TO $50 MILLION IN ENVIRONMENTAL SERVICES TO DADE COUNTY
Topics:


Related Articles
STUDY FINDS ORAL CYTOVENE(R) AN EFFECTIVE ALTERNATIVE FOR MAINTENANCE TREATMENT OF SIGHT-THREATENING CMV RETINITIS
NEW DATA CONFIRM BENEFIT OF CMV PROPHYLAXIS WITH CYTOVENE
ALZA TO PROMOTE BAYER'S MYCELEX(R) TROCHE
ALZA Acquires Mycelex(R) Troche in the U.S. From Bayer
Schering-Plough Reports NOXAFIL(R) (Posaconazole) NDA Granted FDA 6-Month Priority Review for Prevention of Invasive Fungal Infections.
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections.
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections.
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections.
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections.
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters